Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? 

Top 5 Healthcare Headlines for September 28-October 4, 2025:

FDA Approves Guselkumab (Tremfya) for Pediatric Plaque Psoriasis, Psoriatic Arthritis

The FDA approved guselkumab as the first IL-23 inhibitor for children ≥6 years with moderate-to-severe plaque psoriasis or active psoriatic arthritis.

FDA Approves Remibrutinib for Chronic Spontaneous Urticaria

Remibrutinib, a selective BTK inhibitor, gained FDA approval for adults with chronic spontaneous urticaria based on sustained efficacy in phase 3 trials.

Novo Nordisk Resubmits Insulin Icodec (Awiqli) Injection BLA for Type 2 Diabetes

Novo Nordisk resubmitted its once-weekly insulin icodec BLA for type 2 diabetes after addressing prior FDA concerns.

Novo Nordisk Submits Denecimig (Mim8) BLA for Hemophilia A

Novo Nordisk filed a BLA for denecimig as prophylaxis for hemophilia A, supported by FRONTIER program data.

VESALIUS-CV: Evolocumab (Repatha) Achieves Primary Endpoints in Patients with ASCVD

Evolocumab reduced major cardiovascular events in ASCVD patients without prior MI or stroke in the phase 3 VESALIUS-CV trial.

Articles

The FDA has approved guselkumab for pediatric patients with plaque psoriasis and psoriatic arthritis, marking it as the first IL-23 inhibitor for this age group. Remibrutinib, a selective BTK inhibitor, received FDA approval for chronic spontaneous urticaria in adults. Novo Nordisk resubmitted its BLA for insulin icodec for type 2 diabetes and submitted a BLA for denecimig for hemophilia A. Evolocumab demonstrated efficacy in reducing major cardiovascular events in ASCVD patients without prior MI or stroke in the VESALIUS-CV trial.

An audio recap of the top 5 stories in healthcare news from the week of 9/28-10/04.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Hepatology

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

HCPLive 5 Stories in Under 5: Week of 09/28

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

 experience extremely high levels of stress, which can be offset through education and psychological therapy.

T1DM has exhibited an increasing global incidence among adolescents and patients <20 years old. Given the lifelong dependency on insulin brought on by T1DM, as well as glucose monitoring and hypo- and hyperglycemia management, a significant lifestyle change is required for disease management. These processes can be a significant source of stress, particularly in younger patients.

“The purpose of this study was to assess the level of knowledge, stress, and acceptance of the illness in young adults with T1DM and to present the impact of various sociodemographic and medical factors on the level of knowledge, stress, and acceptance of the illness in young adults with T1DM,” Anna Stefanowicz-Bielska, department of pediatrics, diabetology and endocrinology, University Clinical Center of Gdansk, and colleagues wrote.

The study took the form of an interview, conducted between August 2023 and November 2024. Participants were young adults with T1DM who had had the disease for >1 year and were 18-35 years old. The survey included the 

Patients were invited to participate in the survey, which collected sociodemographic data such as gender, age, place of residence, education, professional/school activity, et cetera, medical data related to T1DM such as HbA1c level, illness duration, existence of long-term micro- and macrovascular complications, and T1DM self-monitoring and treatment methods, as well as a knowledge test.

Knowledge was verified using 20 statements concerning T1DM self-monitoring and treatment, which were formatted as correct/incorrect questions. Respondents answered on the definition and treatment of T1DM, the effect of insulin and its administration, principles of glycemia and monitoring, risk factors, symptoms and prevention of hypo- and hyperglycemia, and types of macrovascular complications. Each question was assigned 1 point, with a maximum of 20 points.

A total of 274 patients with T1DM participated in the survey. On average, the participants had T1DM for 13.4 +/- 7.1 years, were treated with a personal insulin pump, had secondary education, were professionally active, and did not smoke or consume alcohol. The average body mass index (BMI) and HbA1c concentration were 25 +/- 4.7 kg/m

 and 7.94 +/- 1.68%, respectively. Median time in range (TIR) was 70.

Median test score was 18/20 – the following statements were the most difficult for respondents:

Type 1 diabetes develops as a result of excessive sugar consumption, overweight, obesity, and lack of physical activity (75.2% correct)

The level of glycemia (glucose concentration) in blood that is correct for an adult with type 1 diabetes is from 80 to 140 (78.1% correct)

Hyperglycemia is diagnosed if the level of glycemia (glucose) in the blood is ≥160-180 mg/dL (79.2% correct), and

Heavy hypoglycemia is a contraindication to physical activity for 24 hours (70.1% correct)

In the stress measurement test, investigators found a positive relationship between the level of stress experienced and the patient’s BMI (raw score: n = 274, R = 0.18, 

 = .00275) and between illness duration and hyperglycemic incidents at night. No relationship was found between stress levels and knowledge levels.

Illness acceptance also saw a negative relationship with HbA1c concentration, as well as with hyperglycemic incidents during the day. However, no relationship was found between the level of acceptance and the level of knowledge.

Investigators went on to discuss alternative methods of relieving this stress and lack of acceptance, citing contemporary self-monitoring technologies. Additionally, Stefanowicz-Bielska and colleagues highlighted the value of educational programs to support patients with T1DM and to help them understand treatment principles.

“Acceptance prevents a decrease in quality of life and reduces the risk of complications related to the illness,” Stefanowicz-Bielska and colleagues wrote. “It is very important during the development of a different way of life, including new rules and limitations.”

Stefanowicz-Bielska A, Rąpała M, Mazuryk K, Dygaszewicz E. Level of knowledge, stress and acceptance of illness in young adults with type 1 diabetes mellitus. Frontiers in Endocrinology. 2025;16. 

Wijk I, Amsberg S, Johansson UB, Livheim F, Toft E, Anderbro T. Impact of an Acceptance and Commitment Therapy programme on HbA1c, self-management and psychosocial factors in adults with type 1 diabetes and elevated HbA1c levels: a randomised controlled trial. BMJ Open. 2023;13(12):e072061. Published 2023 Dec 14. 

Young patients with type 1 diabetes mellitus (T1DM) face significant stress due to the disease's management demands, which can be alleviated through education and psychological therapy. A study assessed knowledge, stress, and illness acceptance in young adults with T1DM, revealing a positive correlation between stress and BMI, and a negative correlation between illness acceptance and HbA1c levels. Despite high knowledge scores, stress and acceptance were not linked to knowledge levels. The study emphasizes the importance of educational programs and self-monitoring technologies in managing T1DM-related stress and improving quality of life.

Lifelong reliance on insulin, constant glucose monitoring, and management of hypo- and hyperglycemia require substantial lifestyle changes.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Adolescent Patients with Type 1 Diabetes Experience Extreme Stress

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

A new analysis has confirmed tildrakizumab’s efficacy in patients with 

 in a real-world setting, with significant improvements in Psoriasis Area and Severity Index (PASI) scores in a heterogeneous patient cohort and notable quality of life improvements.

These findings were the result of a study authored by investigators such as Caroline Glatzel, MD, from the University Hospital Würzburg’s Department of Dermatology, Venereology and Allergology. Glatzel and colleagues set out to assess tildrakizumab’s use in daily practice within a heterogeneous cohort of individuals with psoriasis often impacted by comorbid diseases.

The investigative team highlighted that while the use of biologic drugs in large randomized controlled trials has been observed, such data cannot be directly transferred to patients seen in everyday clinical settings.

“The objective of this analysis was to assess the real-world effectiveness of tildrakizumab, with a particular focus on common comorbidities and factors that may explain discrepancies with the results of the pivotal trials,” Glatzel and coauthors wrote.

Patients evaluated in the investigative team's retrospective, dual-center study were assessed provided they had received tildrakizumab treatment for psoriasis at the University Hospitals of Würzburg and Erlangen between April 2018 - June 2024. Follow-up interactions extending to 76 weeks. Those deemed eligible to be participants were ≥18 years of age and were administered subcutaneous tildrakizumab (100 mg or 200 mg) based on the current standard clinical guidelines. They had been monitored at the 4-week mark and subsequently at 12-week intervals.

Assessments conducted included demographic and clinical data such as body mass index (BMI), duration of psoriasis, sex, previous systemic drug use (non-biologic or biologic), PASI score, age at initiation of tildrakizumab, Dermatology Life Quality Index (DLQI), starting dose, and the presence of comorbidities. Comorbidities were identified by Glatzel et al via patient reports and medical records. Follow-up assessments recorded DLQI scores (Weeks 4–16), PASI outcomes, and any modifications in dosage.

The efficacy analysis concluded with 111 subjects. The investigators determined that the median PASI score declined from 12.6 (IQR 11.0–18.6) at the point of baseline to 6.0 (IQR 1.0–10.4) at the 4-week mark, 1.8 (IQR 1.0–10.4) at the 16-week mark, and 0.0 (IQR 0.0–0.0) at the 76-week mark. Glatzel and coauthors further concluded that the proportion of participants attaining a PASI < 3 was 64.6% at 16 weeks, 79.7% at 52 weeks, and 94.4% at 76 weeks. Additionally, they noted PASI < 5 was achieved by 83.3%, 94.2%, and 100% of subjects at those respective time points.

By the 76-week mark, PASI75, PASI90, and PASI100 responses were attained by 97.2%, 83.3%, and 58.3% of those involved in the study, respectively. Individuals shown to have arterial hypertension (AHT) had a lower PASI response than those without AHT beginning at the 28-week mark (

 = .035) and continuing through follow-up, although those with AHT still reported a score of PASI < 3 by Week 28 and beyond.

Glatzel and colleagues highlighted that individuals with at least a single cardiovascular risk factor (CRF)—defined as dyslipidemia, obesity, AHT, or type 2 diabetes mellitus (46.8%)—were found to have a weaker PASI improvement at the 16, 28, and 64-week marks versus those without such factors (

 = .014, respectively). They further concluded that improvements in median DLQI went from 16.0 (IQR 9.5–22.0) at baseline to 3.0 (IQR 1.0–8.0) during Weeks 4–16, suggesting a substantial enhancement in participants' quality of life.

“Based on these findings, tildrakizumab could be cautiously considered as a potential first-line treatment option for psoriasis patients requiring systemic therapy, especially those with AHT and CRF, though further studies are necessary to confirm its role in this context,” the investigators concluded.

Glatzel C, Fleißner J, Kerstan A, et al. Effectiveness of Tildrakizumab in the Long-Term Treatment of Plaque Psoriasis: A Retrospective, Multicenter Analysis Over 76 Weeks. Dermatologic Therapy, 2025, 6691386, 13 pages, 2025. 

Reich K, Warren RB, Thaçi D, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18. Erratum in: Br J Dermatol. 2022 Jul;187(1):131-132. doi: 10.1111/bjd.20960. PMID: 31218661; PMCID: PMC7064936.

A recent study has validated the real-world efficacy of tildrakizumab in psoriasis patients, demonstrating significant improvements in Psoriasis Area and Severity Index (PASI) scores and quality of life. Conducted by Caroline Glatzel, MD, and colleagues, the study assessed tildrakizumab's effectiveness in a diverse patient cohort, including those with comorbidities. The retrospective analysis involved 111 subjects, revealing substantial PASI score reductions and quality of life enhancements over 76 weeks. Despite lower PASI responses in patients with cardiovascular risk factors, tildrakizumab shows promise as a first-line treatment option.

This study highlighted tildrakizumab’s use in daily practice within a heterogeneous cohort of patients with psoriasis commonly affected by comorbid conditions.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Tildrakizumab Effective in Real-World Settings for Psoriasis Over 76 Weeks

Diana Guzman, LMHC, is the clinical director at 

I’m a clinician, but I’m no more immune to 

 battles than anyone else. Before it all came crashing down a second time, I was living the life I had planned. I was a therapist, a healer, and a confidant for my clients. I had everything I said I wanted, but there was pain lurking behind my strong and confident veneer.

The warning signs were flashing again, but I ignored them, carrying on and projecting strength and stability to those around me. I had been dealing with depression and serious panic attacks, and anxiety for years, but I was managing to keep it together—sort of. I never let anyone in on what was really going on with me.

I thought I could manage it this time, that I could compartmentalize my feelings. But eventually, the cover-up crumbled. I felt utterly alone, despite being surrounded by people who cared. Yes, I was a therapist, but I was also a human being, one who was deeply flawed and in need of help.

The first time I tried to end my life, I was not yet a therapist. I was working at a bank, and it was an ordinary, busy Monday morning. I was with my kids, who were 5 and 6 at the time. I decided to treat them to a Happy Meal at McDonald’s before dropping them off and making my way to work. However, when I drove up to the window and tried to pay, my card was declined.

Feeling a knot in my stomach, I parked the car and quickly checked my bank account, only to discover that it was significantly overdrawn. Confused and a bit embarrassed, I reluctantly took the Happy Meals from my kids' hands and returned them to the cashier.

As I dropped the kids off at school, a wave of sadness hit me like a ton of bricks. Before I knew it, I was crying like crazy, like I was drowning in my tears.

Taking that Happy Meal out of my kids’ hands was one of the worst moments of my life. I felt like a failure. I told myself my kids deserved a better mother. In that moment, I surrendered to the unbearable sadness. Instead of going to work that day, I went home.

I sent my boss a text message saying goodbye. I sent another message to my best friend, also saying goodbye and asking her to tell my kids how much I loved them. Then I made my first attempt to end my life.

Soon after, I felt a blissful release, and everything went dark. When I woke up, I was in a hospital bed.

In reality, I didn’t try to end it all over a Happy Meal. I had been holding onto some heavy stuff buried deep inside: childhood sexual abuse, rape, and domestic violence. I was also dealing with an all-consuming feeling of abandonment and inadequacy, and I just couldn’t talk about any of it. So, I didn’t. And what they say is true: silence kills.

I survived that attempt and kept going, but the thoughts of suicide never really left me. I lived with severe depression and anxiety that got so bad I started shoving furniture behind my doors out of fear.

But I just kept pushing my struggles to the side. I juggled school, work, and 2 kids all on my own. It was tough, really tough. Some days, I'd find myself daydreaming about ending it all and thinking about the “easiest” ways to do it. The only thing that kept me going was this little flicker of hope that I could turn things around for myself. I forged ahead, working toward my dream career as a therapist.

In my first counseling job, I felt like things were going as planned until I took on a young client whose life experiences mirrored mine. A friend of mine always says, "What you resist persists.” Well, that was true because suddenly, I was face-to-face with everything I had avoided dealing with for years.

When she told me her story, it felt like she was telling my story too. Sessions with her brought up everything I had struggled to push down for years.

After bringing up my concerns about treating her to my boss, I was told to get over it and do my job. This led me to a very dark place. I ended up attempting to take my life again.

After a long and bumpy road that included a third suicide attempt, I can say: I’m still here. Through unwavering perseverance and the support of loved ones, I found the courage to reach out for help. I sought therapy myself, a humbling experience for someone who had spent years on the other side of the couch.

I now understand that clinicians are not immune to the challenges and emotional burdens faced by our clients. We, too, go through our own struggles and must seek support when needed.

Today, I stand before you not just as a survivor but as an advocate for open discussions about mental illness. At a certain point in my journey, I realized that my fight wasn't just with my illness, but also with the perceptions and attitudes that often come with it.

I’ve made a heartfelt decision to no longer keep my story to myself. I want to speak up and be heard. I refuse to be silent because I believe that healing happens when we stop blaming each other for our mental health challenges, when our pain is acknowledged, and when we can bring these conversations into the light without feeling ashamed.

Vulnerability does not equate to weakness; rather, it is a strength that fosters connection and empathy. Sharing my story has become a crucial part of my healing process and a way to inspire hope in others.

It’s in those vulnerable, sometimes uncomfortable discussions that we find connection and understanding. And these moments can truly save lives.

A clinician shares their personal journey through mental health struggles, highlighting the challenges faced despite being a therapist. They recount experiences of depression, anxiety, and multiple suicide attempts, emphasizing the importance of seeking help and breaking the silence surrounding mental health issues. The narrative underscores the need for open discussions about mental illness, advocating for vulnerability as a strength that fosters connection and empathy. By sharing their story, they aim to inspire hope and encourage others to seek support, ultimately contributing to a broader understanding of mental health challenges.

Therapist Diana Guzman, LMHC, writes about attempting suicide despite counseling patients battling with suicidal ideation. 

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

I Tried to End My Life 3 Times: Today, I Help Others Fight for Theirs

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration (FDA) approvals of guselkumab (Tremfya) for pediatric 

), 2 regulatory submissions from Novo Nordisk for insulin icodec (Awiqli) injection for 

 and denecimig (Mim8) for hemophilia A, and phase 3 data for evolocumab (Repatha) in patients with 

atherosclerotic cardiovascular disease (ASCVD)

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of September 28, 2025—let’s jump in!

On September 29, 2025, the FDA approved Johnson & Johnson’s guselkumab (Tremfya) for the treatment of children ≥ 6 years of age who also weigh ≥ 40 kg (88 lbs) with moderate to severe PsO, who are candidates for systemic therapy or phototherapy, or active PsA. The decision makes guselkumab the first and only IL-23 inhibitor approved for these pediatric indications.

On September 30, 2025, the FDA approved Novartis’ remibrutinib (Rhapsido), a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, for adults with CSU. The decision was supported by data from the phase 3 REMIX-1 and REMIX-2 trials showing that remibrutinib produced early and substantial reductions in CSU symptoms, with improvements sustained for up to 52 weeks.

On September 29, 2025, Novo Nordisk announced the resubmission of its Biologics License Application (BLA) to the FDA for insulin icodec (Awiqli) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program and follows a July 2024 CRL over concerns regarding the manufacturing process and the type 1 diabetes indication.

On September 29, 2025, Novo Nordisk announced the submission of a Biologics License Application (BLA) for denecimig (Mim8) as a prophylaxis treatment to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital FVIIIa deficiency), with or without inhibitors. The submission was supported by results from the FRONTIER study program.

On October 2, 2025, Amgen announced positive results from the phase 3 VESALIUS-CV trial of evolocumab (Repatha) in patients with ASCVD and no prior history of 

. The trial met its dual primary endpoints for time to first occurrence of a composite of heart attack, ischemic stroke, and coronary heart disease (CHD) death, as well as time to first occurrence of a composite of CHD death, ischemic stroke, heart attack, or any ischemia-driven arterial revascularization.

The FDA has approved guselkumab (Tremfya) for pediatric plaque psoriasis and psoriatic arthritis, marking it as the first IL-23 inhibitor for these indications. Remibrutinib (Rhapsido) has also been approved for chronic spontaneous urticaria, demonstrating significant symptom reduction. Novo Nordisk resubmitted its BLA for insulin icodec (Awiqli) for type 2 diabetes and submitted a BLA for denecimig (Mim8) for hemophilia A. Evolocumab (Repatha) achieved primary endpoints in the VESALIUS-CV trial for patients with atherosclerotic cardiovascular disease.

Stay updated with the latest healthcare breakthroughs, including FDA news, regulatory submissions, and evolocumab data for ASCVD, in this week's essential news roundup.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The HCPFive: Top News for Healthcare Providers from the Week of 09/28

Recent research refutes the conception that most, if not all, coronary heart disease occurs without typical CVD risk factors.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

99% of Heart Attacks, Strokes, Heart Failures Have Cardiovascular Risk Factors Beforehand

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Q3 2025 Recap: 7 Pulmonology Updates to Know

This analysis assesses the positive predictive value of the ICD-10 code for vitiligo commonly used in electronic medical record-based research.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

ICD-10 Code Demonstrates High Level of Accuracy for Identifying Vitiligo

Clinical Associate Professor, University of Calgary, Councilor for the International Psoriasis Council, as well as Co-Founder and Co-Director of the Skin Health & Wellness Centre, Dermatology Research Institute, and Dermphi Centre

Videos

Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

FDA News

Bridging the Treatment Gap in Pediatric Psoriasis and PsA With Guselkumab, With Vimal H. Prajapati, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Emerging research highlights the critical link between sleep quality and cardiovascular health.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Q3 2025 Recap: Sleep Medicine News and Updates

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Chronic Kidney Disease

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Q3 2025 Recap: Nephrology News and Updates

Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Cardiomyopathy

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Expert Perspectives: Top News in Heart Failure from HFSA Annual Scientific Meeting 2025

Read about new AGA gastroparesis guidelines, GI FDA news, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

5 Gastroenterology Headlines You Missed in September 2025

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from EADV.

HCPLive Five - Dermatology Updates at EADV Congress 2025

Panelists discuss how modern topical treatments have evolved beyond traditional corticosteroids to include more effective nonsteroidal options, such as tapinarof and roflumilast, which provide better long-term control and can complement systemic therapies.

Latest News

HCPLive 5 Stories in Under 5: Week of 09/28

Adolescent Patients with Type 1 Diabetes Experience Extreme Stress

Tildrakizumab Effective in Real-World Settings for Psoriasis Over 76 Weeks

I Tried to End My Life 3 Times: Today, I Help Others Fight for Theirs

The HCPFive: Top News for Healthcare Providers from the Week of 09/28